Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04915924
Other study ID # ABT-CIP-10344
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 30, 2020
Est. completion date December 31, 2024

Study information

Verified date January 2024
Source Abbott Medical Devices
Contact Evonne Poon
Phone +65 69148433
Email evonnesueyin.poon@abbott.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Korea HM3 PMS is a prospective, single arm, open-label, multi-center, post market surveillance is designed to evaluate clinical and functional outcomes with the HM3 LVAS as a treatment for advanced heart failure. The PMS will enroll up to 300 patients, that meet the Health Insurance Review and Assessment (HIRA) guidelines for LVAD implantation, from up to 25 sites in South Korea. Subjects who will be implanted but not included in the PMS can be enrolled retrospectively after obtaining their informed consent. The surveillance period for this PMS is expected to be 4 years from the time of HM3 approval in Korea, concluding on June 2, 2024.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date December 31, 2024
Est. primary completion date June 2, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria General Inclusion Criteria: All patients approved for HM3 implantation in Korea as per HIRA guidelines will be eligible to be enrolled in the PMS. Only the patients who provide written informed consent will be included in the study. If a subject has had an outcome after the HM3 implantation but prior to providing informed consent, no consent will be obtained, and a limited anonymized data will be collected. Exclusion Criteria General Exclusion Criteria: This post market surveillance does not have specific exclusion criteria

Study Design


Related Conditions & MeSH terms


Intervention

Device:
HeartMate 3™ left ventricular assist system (HM3 LVAS)
Advanced heart failure patients will be implanted with the HM3 LVAS

Locations

Country Name City State
Korea, Republic of Korea University Ansan Hospital Ansan
Korea, Republic of Sejong Hospital Bucheon
Korea, Republic of Pusan National University Hospital Busan
Korea, Republic of Gyeongsang National University Changwon Hospital Changwon
Korea, Republic of Keimyung University Dongsan Medical Center Daegu
Korea, Republic of Kyungpook National University Hospital Daegu
Korea, Republic of Chungnam National University Hospital Daejeon
Korea, Republic of Chonnam National University Hospital (CNUH) Gwangju
Korea, Republic of Hallym University Dongtan Sacred Heart Hospital Hwaseong
Korea, Republic of Hallym University Sacred Heart Hospital Hwaseong
Korea, Republic of Seoul National University Hospital Ihwa-dong
Korea, Republic of Gachon University Gil Hospital Incheon
Korea, Republic of Incheon Sejong Hospital Incheon Nam-gu
Korea, Republic of Seoul National University Bundang Hospital Seongnam-si
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Gangnam Severance Hospital Seoul
Korea, Republic of Korea University Anam Hospital Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul St. Mary's Hospital Seoul
Korea, Republic of Severance Hospital, Yonsei University Health System Seoul
Korea, Republic of St. Mary's Hospital, The Catholic University of Eunpyeong Seoul
Korea, Republic of Pusan National University Yangsan Hospital Yangsan

Sponsors (1)

Lead Sponsor Collaborator
Abbott Medical Devices

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Efficacy Endpoint: Number of participants with overall survival to transplant, myocardial recovery or on device support free of debilitating stroke (60 days post-stroke Modified Rankin Score >3) or reoperation for pump replacement Overall survival to transplant, myocardial recovery or on device support free of debilitating stroke (60 days post-stroke Modified Rankin Score >3) or reoperation for pump replacement will be assessed using the Kaplan-Meier product-limit method along with a competing outcomes graph. Subjects who are urgently transplanted due to a HeartMate 3 malfunction will be considered to have experienced a primary endpoint event, as will subjects who expire, suffer a debilitating stroke or have their HeartMate 3 exchanged due to a device failure. Subjects who are transplanted (except as described above), explanted for recovery, withdraw from the trial or are lost to follow-up will be censored at that time in the analysis. Throughout the study (approximately 4 years)
Primary Primary Safety Endpoint: Number of cumulative occurrence of adverse events Cumulative occurrence of adverse events will be presented as percent of patients with adverse events and events per patient year of support. Throughout the study (approximately 4 years)
Secondary Mean change in Six-minute Walk Test from baseline The 6-minute Walk test will be conducted at all follow-up visits until the end of the surveillance period. Distance walked at each visit will be compared to baseline using Wilcoxon signed-rank test. To assess the overall changes, repeated measure analysis will be performed using all data collected from baseline to the end of the surveillance period. The overall mean, median, standard deviation, minimum, and maximum will be presented for all follow-up visits. Differences in walking distance between each visit and baseline will be calculated and assessed for improvements using paired, nonparametric Wilcoxon signed-rank test. In addition, box plots will be used to show changes in walking distance over time. Through study completion, an average of 4 years
Secondary Change in proportion of New York Heart Association (NYHA) Functional Status from baseline Percent of subjects in each NYHA class will be presented for all follow-up visits. For comparison, patients will be grouped into NYHA Class I/II (No limitation and Slight limitation of physical activity) vs. NYHA Class III/IV (Marked limitation and Inability to carry out physical activities). McNemar's test will be used to assess if there is an increase in proportion of Class I and II subjects at each visit comparing to the baseline. Through study completion, an average of 4 years
Secondary Mean change in EQ-5D-5L quality of life (QoL) from baseline Subject's quality of life will be measured by the EQ-5D-5L QoL questionnaire at baseline and all visits after HM3 implant until the end of surveillance period. The overall mean, median, standard deviation, minimum and maximum will be presented for all follow-up visits. Differences in QoL Score between each visit and baseline will be calculated and assessed for improvements using paired, nonparametric Wilcoxon signed-rank test. In addition, box plots will be used to show changes in QoL over time. Through study completion, an average of 4 years
Secondary Frequency of Rehospitalization and Reoperation Frequency and reason will be reported for rehospitalization and reoperation. Freedom from rehospitalization and reoperation will be assessed using the Kaplan-Meier product-limit method. Throughout the study (approximately 4 years)
Secondary Number of participants with Device Malfunctions All suspected HM3 device malfunctions will be reported. Device malfunctions will be collected under the general category of Device Deficiencies. Device deficiency is defined as an inadequacy of a medical device related to its identity, quality, durability, reliability, safety or performance, such as malfunction, misuse or use error and inadequate labeling. This includes the failure of the device to meet its performance specifications or otherwise perform as intended. Data on device malfunctions will be analyzed for the following:
The component of the device involved
Days to the malfunction
Action taken in response to the malfunction
Reoperations due to malfunction
Death due to malfunction
Throughout the study (approximately 4 years)
Secondary Incidence of adverse events including, but not limited to, neurological dysfunction, bleeding, infections and device thrombosis. Incidence of adverse events will be assessed including, but not limited to, neurological dysfunction, bleeding, infections and device thrombosis. Throughout the study (approximately 4 years)
See also
  Status Clinical Trial Phase
Suspended NCT02962973 - European Clinical Evaluation of the Carmat Total Artificial Heart N/A
Completed NCT01626404 - Screening for Advanced Heart Failure Treatment (SEE-HF)
Withdrawn NCT00572286 - Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study N/A
Completed NCT00690157 - Registry of Patients Referred for Heart Transplantation N/A
Active, not recruiting NCT03874312 - Ultrasound-assessed Internal Jugular Vein Distensibility in Advanced Chronic Heart Failure (US-IJVD in CHF)
Enrolling by invitation NCT00988806 - Long-Term Intermittent Administration of Levosimendan in Patients With Advanced Heart Failure Phase 4
Recruiting NCT05284955 - Screening for Advanced Heart Failure IN Stable outPatientS - The SAINTS Study (SAINTS B) Phase 4
Completed NCT01643551 - Neuron Specific Enolase in Ventricular Assist Device Recipients N/A
Terminated NCT04703855 - Hong Kong and Taiwan HM3 PMS N/A
Suspended NCT04851236 - Pilot Study of Massage Therapy to Improve Self Efficacy in Patients With Left-ventricular Device Early Phase 1
Recruiting NCT03526627 - Advanced Care Management in Patients With Advanced Heart Failure
Recruiting NCT06228209 - Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer N/A
Active, not recruiting NCT06259045 - Cardiac Cachexia in Advanced Heart Failure
Recruiting NCT05271214 - Conservative Management of Left Ventricular Assist Device Candidates
Recruiting NCT04475393 - Carmat Total Artificial Heart as a Bridge to Transplant in Patients With Advanced Heart Failure N/A
Recruiting NCT03911349 - Wrist Worn Blood Pressure Measurement N/A
Recruiting NCT03919136 - Wrist Worn Blood Pressure Measurement
Completed NCT01210573 - Prospective Observation of Exercise Parameters in Advanced Heart Failure N/A
Recruiting NCT04423562 - PROgnostic Value of Exercise Capacity Measured as Peak Oxygen Uptake (pVO2) in Recipients of Left Ventricular Assist Devices